Frontiers in Pharmacology (Nov 2024)
Expert consensus on the off-label use in China of drugs for rare hematologic diseases (2024 edition)
- Boxin Zhao,
- Boxin Zhao,
- Xuan Zhou,
- Ping Zheng,
- Ping Zheng,
- Bo Zhang,
- Bo Zhang,
- Xiaoqin Feng,
- Jie Chen,
- Lisheng Cai,
- Yilu Chen,
- Liya He,
- Jianfen Su,
- Shuqin Cheng,
- Yingtong Zeng,
- Guowei Li,
- Bo Ji,
- Jianlong Wu,
- Weiyi Feng,
- Maobai Liu,
- Yiran Jin,
- Taotao Liu,
- Xiaolan Mo,
- Junyan Wu,
- Hui Wu,
- Hongliang Zhang,
- Zhichang Zheng,
- Zhihua Zheng,
- Jing Sun,
- Yilei Li,
- Yilei Li,
- Guangdong Pharmaceutical Association, Hematology Group of Rare Disease Expert Committee of Guangdong Pharmaceutical Association
Affiliations
- Boxin Zhao
- Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Boxin Zhao
- Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Xuan Zhou
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Ping Zheng
- Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Ping Zheng
- Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Bo Zhang
- Department of Pharmacy, Peking Union Medical College Hospital, Beijing, China
- Bo Zhang
- State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China
- Xiaoqin Feng
- Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Jie Chen
- Department of Pharmacy, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- Lisheng Cai
- Department of Hematology, Shenzhen Second People’s Hospital, Shenzhen, China
- Yilu Chen
- Department of Pharmacy, Guangzhou Women and Children’s Medical Center, Guangzhou, China
- Liya He
- 0Department of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou, China
- Jianfen Su
- 1Department of Pharmacy, Panyu Central Hospital, Guangzhou, China
- Shuqin Cheng
- 2Department of Hematology, Panyu Central Hospital, Guangzhou, China
- Yingtong Zeng
- 3Department of Pharmacy, Guangdong Provincial People’s Hospital, Southern Medical University, Guangzhou, China
- Guowei Li
- 4Department of Hematology, Huizhou Central People’s Hospital, Huizhou, China
- Bo Ji
- 5Department of Clinical Pharmacy, General Hospital of Southern Theatre Command of PLA, Guangzhou, China
- Jianlong Wu
- 6Department of Pharmacy, Shenzhen Second People’s Hospital, Shenzhen, China
- Weiyi Feng
- 7Department of Pharmacy, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
- Maobai Liu
- 8Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China
- Yiran Jin
- 9Department of Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang, China
- Taotao Liu
- 0Pharmacy Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Xiaolan Mo
- Department of Pharmacy, Guangzhou Women and Children’s Medical Center, Guangzhou, China
- Junyan Wu
- 1Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
- Hui Wu
- 2Department of Pharmacy, First Affiliated Hospital of Kunming Medical University, Kunming, China
- Hongliang Zhang
- 0Pharmacy Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Zhichang Zheng
- 3Department of Pharmacy, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
- Zhihua Zheng
- 4Guangdong Pharmaceutical Association, Guangzhou, China
- Jing Sun
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Yilei Li
- Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Yilei Li
- Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Guangdong Pharmaceutical Association, Hematology Group of Rare Disease Expert Committee of Guangdong Pharmaceutical Association
- DOI
- https://doi.org/10.3389/fphar.2024.1477550
- Journal volume & issue
-
Vol. 15
Abstract
Drug package inserts are a crucial foundation for clinical medication practices and serve as the legal basis for guiding rational drug use and ensuring patient safety and efficacy. As rare disease treatments evolve, current package inserts often need to meet the clinical requirements for treating such conditions, frequently resulting in off-label drug use. This consensus is derived from discussions between Guangdong Pharmaceutical Association Hematologic Rare Diseases Group experts. The consensus aims to provide a framework and reference for the clinical application of off-label drug use in treating rare hematologic diseases.
Keywords
